CN101768152A - 用作ccr5拮抗剂的哌啶衍生物 - Google Patents

用作ccr5拮抗剂的哌啶衍生物 Download PDF

Info

Publication number
CN101768152A
CN101768152A CN200910266072A CN200910266072A CN101768152A CN 101768152 A CN101768152 A CN 101768152A CN 200910266072 A CN200910266072 A CN 200910266072A CN 200910266072 A CN200910266072 A CN 200910266072A CN 101768152 A CN101768152 A CN 101768152A
Authority
CN
China
Prior art keywords
alkyl
compound
aryl
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200910266072A
Other languages
English (en)
Chinese (zh)
Inventor
M·W·米勒
J·D·史考特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101768152A publication Critical patent/CN101768152A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CN200910266072A 2002-12-18 2003-12-17 用作ccr5拮抗剂的哌啶衍生物 Pending CN101768152A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43430602P 2002-12-18 2002-12-18
US60/434306 2002-12-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200380107119A Division CN100591678C (zh) 2002-12-18 2003-12-17 用作ccr5拮抗剂的哌啶衍生物

Publications (1)

Publication Number Publication Date
CN101768152A true CN101768152A (zh) 2010-07-07

Family

ID=32682021

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200910266072A Pending CN101768152A (zh) 2002-12-18 2003-12-17 用作ccr5拮抗剂的哌啶衍生物
CN200380107119A Expired - Fee Related CN100591678C (zh) 2002-12-18 2003-12-17 用作ccr5拮抗剂的哌啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200380107119A Expired - Fee Related CN100591678C (zh) 2002-12-18 2003-12-17 用作ccr5拮抗剂的哌啶衍生物

Country Status (16)

Country Link
US (2) US7307081B2 (https=)
EP (1) EP1581494A2 (https=)
JP (1) JP4589728B2 (https=)
KR (1) KR20050085700A (https=)
CN (2) CN101768152A (https=)
AR (1) AR042481A1 (https=)
AU (1) AU2003297400B2 (https=)
CA (1) CA2510027A1 (https=)
CL (1) CL2003002637A1 (https=)
MX (1) MXPA05006580A (https=)
MY (1) MY147899A (https=)
NZ (1) NZ540452A (https=)
PE (1) PE20040769A1 (https=)
TW (1) TWI331606B (https=)
WO (1) WO2004056770A2 (https=)
ZA (1) ZA200504772B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015517B1 (ru) 2004-04-13 2011-08-30 Инсайт Корпорейшн Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071875A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
JP4822367B2 (ja) * 2005-02-23 2011-11-24 シェーリング コーポレイション ケモカイン受容体のインヒビターとして有用なピペリジニルピペリジン誘導体
EP1858887A1 (en) * 2005-02-23 2007-11-28 Schering Corporation Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
JP2009517474A (ja) * 2005-11-30 2009-04-30 シェーリング コーポレイション Ｃｃｒ５拮抗剤およびｃｘｃｒ４拮抗剤の組み合わせを含む組成物
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
CA2673233A1 (en) * 2006-12-22 2008-07-03 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
JP7611949B2 (ja) * 2023-01-27 2025-01-10 株式会社Ｓｃｒｅｅｎホールディングス 基板保持装置及びそれを備えた基板処理装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079194A1 (en) * 2001-03-29 2002-10-10 Schering Corporation Ccr5 antagonists useful for treating aids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
KR100439357B1 (ko) * 1999-05-04 2004-07-07 쉐링 코포레이션 Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체
SK287418B6 (sk) * 1999-05-04 2010-09-07 Schering Corporation Farmaceutický prípravok s obsahom CCR5 antagonistov a súprava s obsahom tohto prípravku
JP4303969B2 (ja) * 2001-03-29 2009-07-29 シェーリング コーポレイション Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079194A1 (en) * 2001-03-29 2002-10-10 Schering Corporation Ccr5 antagonists useful for treating aids

Also Published As

Publication number Publication date
WO2004056770A2 (en) 2004-07-08
US20040132711A1 (en) 2004-07-08
AR042481A1 (es) 2005-06-22
JP2006515851A (ja) 2006-06-08
TW200427682A (en) 2004-12-16
CL2003002637A1 (es) 2005-04-08
NZ540452A (en) 2008-12-24
AU2003297400A1 (en) 2004-07-14
KR20050085700A (ko) 2005-08-29
US20080095740A1 (en) 2008-04-24
EP1581494A2 (en) 2005-10-05
CN1729186A (zh) 2006-02-01
TWI331606B (en) 2010-10-11
AU2003297400B2 (en) 2010-03-11
PE20040769A1 (es) 2004-11-06
MY147899A (en) 2013-01-31
JP4589728B2 (ja) 2010-12-01
US7307081B2 (en) 2007-12-11
ZA200504772B (en) 2006-03-29
WO2004056770A3 (en) 2004-08-12
MXPA05006580A (es) 2005-08-16
CA2510027A1 (en) 2004-07-08
CN100591678C (zh) 2010-02-24

Similar Documents

Publication Publication Date Title
US8034933B2 (en) Piperidine derivatives useful as CCR5 antagonists
CA2442227C (en) Ccr5 antagonists useful for treating aids
AU2002255947A1 (en) CCR5 antagonists useful for treating AIDS
US20080095740A1 (en) Piperidine derivatives useful as ccr5 antagonists
CN1898231B (zh) 用作趋化因子受体抑制剂的双六氢吡啶衍生物
EP1996576A1 (en) Ccr5 antagonists useful for treating hiv
US7659275B2 (en) Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
US7705019B2 (en) Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
MXPA06004963A (en) Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
AU2002329889A1 (en) Piperidine derivatives useful as CCR5 antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100707